Drug Profile
Asalhydromorphone - Zevra Therapeutics
Alternative Names: Asal-HM; Hydromorphone extended release - Zevra Therapeutics; Hydromorphone immediate release - Zevra Therapeutics; KP 511/ER; KP 511/IR; KP511 APILatest Information Update: 26 Feb 2023
Price :
$50
*
At a glance
- Originator KemPharm
- Developer Zevra Therapeutics
- Class Benzoates; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute pain
Most Recent Events
- 22 Feb 2023 KemPharm is now called Zevra Therapeutics
- 28 Dec 2020 No recent reports of development identified for clinical-Phase-Unknown development in Acute pain in USA (PO, Immediate release)
- 02 Aug 2019 Chemical structure information added